Results of micropulse transscleral cyclophotocoagulation for the treatment of glaucoma

Purpose. To evaluate the clinical effectiveness and safety of transscleral micropulse cyclophotocoagulation (mCPC) in the treatment of patients with early, advanced and terminal stages of open-angle glaucoma using the Cyclo G6 Glaucoma Laser System (IRIDEX, USA). Assess the dynamics of IOP reduction, the number of antihypertensive drugs and complications after mCPC over a period of up to 6 months. Material and methods. A retrospective analysis was conducted of 50 eyes of 46 patients aged 71 ± 6.3 years with primary open-angle glaucoma of initial (7), mature (11), advanced (16) and terminal (16) stages, who underwent mCFC in the period from 2021 to 2023 with an observation period of at least 6 months after treatment. Patients were observed on the 1st, 7th day, and then 1 and 6 months after treatment. Results.The hypotensive effect persisted throughout the entire observation period. Eight patients with uncompensated IOP underwent repeat mCFC, on average three months after the first intervention. It was not possible to achieve a reduction in the medication load. During the entire observation period, best-corrected visual acuity (BCVA) remained at the preoperative level (on average 0.5 ± 0.3). Conclusion. Micropulse transscleral cyclophotocoagulation has been shown to be effective in reducing intraocular pressure and has been shown to be a safe and effective treatment for glaucoma. However, it is important to understand that the duration of follow-up considered in this study (6 months) is short compared to the gradual progression of glaucoma. Further studies and follow-up over several years will be required to evaluate the long-term effectiveness of mCFC in patients with glaucoma.